NO20005161L - N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer - Google Patents

N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer

Info

Publication number
NO20005161L
NO20005161L NO20005161A NO20005161A NO20005161L NO 20005161 L NO20005161 L NO 20005161L NO 20005161 A NO20005161 A NO 20005161A NO 20005161 A NO20005161 A NO 20005161A NO 20005161 L NO20005161 L NO 20005161L
Authority
NO
Norway
Prior art keywords
binding
receptors
inhibit
integrins
compounds
Prior art date
Application number
NO20005161A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005161D0 (no
Inventor
Jamal M Kassir
Ronald J Biediger
Vanessa O Grabbe
Shuqun Lin
Robert V Market
Bore G Raju
Ian L Scott
Timothy P Kogan
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of NO20005161D0 publication Critical patent/NO20005161D0/no
Publication of NO20005161L publication Critical patent/NO20005161L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO20005161A 1998-04-16 2000-10-13 N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer NO20005161L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8201998P 1998-04-16 1998-04-16
PCT/US1999/008302 WO1999052898A1 (en) 1998-04-16 1999-04-15 N,n-disubstituted amides that inhibit the binding of integrins to their receptors

Publications (2)

Publication Number Publication Date
NO20005161D0 NO20005161D0 (no) 2000-10-13
NO20005161L true NO20005161L (no) 2000-12-15

Family

ID=22168519

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20005161A NO20005161L (no) 1998-04-16 2000-10-13 N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer
NO20005162A NO20005162L (no) 1998-04-16 2000-10-13 Forbindelser som inhiberer bindingen av integriner til deres reseptorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20005162A NO20005162L (no) 1998-04-16 2000-10-13 Forbindelser som inhiberer bindingen av integriner til deres reseptorer

Country Status (20)

Country Link
US (3) US6096773A (de)
EP (2) EP1071680B1 (de)
JP (2) JP4753403B2 (de)
KR (2) KR20010042704A (de)
CN (2) CN1305473A (de)
AT (2) ATE474573T1 (de)
AU (2) AU3563799A (de)
BR (2) BR9909626A (de)
CA (2) CA2328990C (de)
DE (2) DE69939165D1 (de)
ES (2) ES2345471T3 (de)
HU (2) HUP0101419A3 (de)
ID (1) ID28658A (de)
IL (2) IL138972A0 (de)
NO (2) NO20005161L (de)
NZ (1) NZ507534A (de)
PL (2) PL343770A1 (de)
SK (2) SK15592000A3 (de)
TR (2) TR200100139T2 (de)
WO (2) WO1999052898A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
HUP0101419A3 (en) 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
TW593284B (en) 1999-01-22 2004-06-21 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
AR035838A1 (es) 1999-01-22 2004-07-21 Elan Pharm Inc Compuestos multiciclicos que inhiben la adhesion de leucocitos mediada por vla-4 y el uso de los mismos para la preparacion de un medicamento
HK1045157A1 (zh) 1999-01-22 2002-11-15 依兰制药公司 抑制vla-4介导的白细胞粘着的化合物
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
YU41202A (sh) 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
DE60141889D1 (de) 2000-02-03 2010-06-02 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
CN1423635A (zh) * 2000-04-14 2003-06-11 吴羽化学工业株式会社 含氮化合物以及使用该化合物的抗病毒药
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
US20040157818A1 (en) * 2001-05-24 2004-08-12 Mikiro Yanaka Cxcr4-antagonistic drugs composed of nitrogen-containing compound
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
WO2003029218A1 (en) * 2001-09-28 2003-04-10 Kureha Chemical Industry Company, Limited Novel nitrogenous compound and use thereof
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
US7122580B2 (en) * 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
KR100863667B1 (ko) 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7544699B2 (en) * 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
KR101149124B1 (ko) * 2004-03-10 2012-05-25 가부시끼가이샤 구레하 아민계 염기성 화합물과 그의 용도
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
EA017110B1 (ru) 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
EP2303308A4 (de) 2008-05-13 2012-11-07 Clarassance Inc Rekombinanter humaner cc10 und zusammensetzungen dafür zur verwendung bei der behandlung von nasaler rhinitis
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
ES2677668T3 (es) * 2010-11-16 2018-08-06 Texas Heart Institute Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
US11484524B2 (en) 2014-07-01 2022-11-01 7 Hills Pharma LLC Compositions and methods to improve adoptive cell therapies
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3860660A4 (de) * 2018-10-05 2023-01-25 Texas Heart Institute Bildgebungsmittel und verfahren zur verwendung
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN117551012A (zh) * 2022-08-06 2024-02-13 山东康乔生物科技有限公司 一种含苄基结构的取代酰基苯胺类化合物的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372974A (en) * 1980-06-25 1983-02-08 New York University Anticonvulsive compositions and method of treating convulsive disorders
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
EP0422398A3 (en) 1989-10-12 1992-07-08 International Business Machines Corporation A method of optimizing a computer program by removing invariant branches from loops
NZ235564A (en) 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
DE69425431T2 (de) 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
JPH06298797A (ja) * 1993-04-12 1994-10-25 Fuji Photo Film Co Ltd ペプチド誘導体およびその用途
JP3190765B2 (ja) * 1993-05-13 2001-07-23 富士写真フイルム株式会社 ペプチド誘導体及びその用途
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JP2000516596A (ja) * 1996-07-25 2000-12-12 バイオジェン，インコーポレイテッド 細胞接着インヒビター
KR20010022414A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
DK1027328T3 (da) * 1997-10-31 2006-11-13 Aventis Pharma Ltd Substituerede anilider
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
SK9192000A3 (en) * 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
HUP0101419A3 (en) 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO20005161D0 (no) 2000-10-13
AU3563799A (en) 1999-11-01
US6262084B1 (en) 2001-07-17
IL138972A0 (en) 2001-11-25
CN1311676A (zh) 2001-09-05
PL343770A1 (en) 2001-09-10
TR200100141T2 (tr) 2001-06-21
HUP0101419A2 (hu) 2002-04-29
KR20010087125A (ko) 2001-09-15
SK15602000A3 (sk) 2001-03-12
DE69939165D1 (de) 2008-09-04
JP2002511397A (ja) 2002-04-16
HUP0103752A3 (en) 2002-11-28
WO1999052493A3 (en) 2000-12-28
ES2345471T3 (es) 2010-09-23
CA2328990A1 (en) 1999-10-21
CA2328234C (en) 2009-03-17
EP1079825B1 (de) 2010-07-21
ATE474573T1 (de) 2010-08-15
ATE402170T1 (de) 2008-08-15
US6096773A (en) 2000-08-01
SK15592000A3 (sk) 2001-12-03
US6194448B1 (en) 2001-02-27
IL138973A0 (en) 2001-11-25
JP4753403B2 (ja) 2011-08-24
JP4949552B2 (ja) 2012-06-13
DE69942610D1 (de) 2010-09-02
TR200100139T2 (tr) 2001-06-21
EP1071680A1 (de) 2001-01-31
AU3748399A (en) 1999-11-01
HUP0103752A2 (hu) 2002-07-29
CA2328990C (en) 2011-01-11
HUP0101419A3 (en) 2002-08-28
CA2328234A1 (en) 1999-10-21
KR20010042704A (ko) 2001-05-25
BR9909625A (pt) 2002-01-15
WO1999052898A1 (en) 1999-10-21
ES2308839T3 (es) 2008-12-01
PL346220A1 (en) 2002-01-28
EP1079825A2 (de) 2001-03-07
ID28658A (id) 2001-06-21
BR9909626A (pt) 2002-01-15
JP2002511463A (ja) 2002-04-16
NZ507534A (en) 2002-02-01
EP1071680B1 (de) 2008-07-23
CN1305473A (zh) 2001-07-25
NO20005162L (no) 2000-12-15
WO1999052493A2 (en) 1999-10-21
NO20005162D0 (no) 2000-10-13
EP1071680A4 (de) 2003-03-05
EP1079825A4 (de) 2003-03-05

Similar Documents

Publication Publication Date Title
NO20005162L (no) Forbindelser som inhiberer bindingen av integriner til deres reseptorer
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
ATE420876T1 (de) Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
DK1203766T3 (da) Carboxylisyrederivater, der hæmmer bindingen af integriner til deres receptorer
ATE277923T1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
NO20000841L (no) N-Aroylfenylalanin-derivater
BR9810712A (pt) Processo para a prevenção ou tratamento de prurido em um paciente
BRPI9715334B8 (pt) agentes estrogênicos e composição farmacêutica compreendendo os mesmos.
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
FI954914A7 (fi) Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin esto n, säätelyn tai regression aikaansaamiseksi
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
NO993435L (no) Transdermalt acetylsalicylsyre inneholdende terapeutisk system med forsterket resorpsjon
DE69709891D1 (de) Chitosan enthaltende zusammensetzung
BR9807920A (pt) Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
GT199800028A (es) Metodo de purificacion de 1, 3, 5-triisopropilbenceno.
NO950114L (no) Amylin-antagonister og agonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application